MedTrace Logo

Antifungal Drugs in Pulmonary Mucormycosis

NCT06756191 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 312

Last updated 2025-01-01

No results posted yet for this study

Summary

Pulmonary mucormycosis (PM) poses a substantial clinical challenge, particularly among immunocompromised patients. The aim of the study is to determine the effectiveness and safety of administering AmBisome at a dose of 5mg/kg/day combined with isavuconazole versus using AmBisome for the management of pulmonary mucormycosis

Conditions

  • Pulmonary Mucormycosis

Interventions

DRUG

Combination therapy group

Liposomal amphotericin B (AmBisome®) combination with Isavuconazole

DRUG

Liposomal Amphotericin B

Liposomal amphotericin B (AmBisome®) alone

Sponsors & Collaborators

  • Bin Cao

    lead OTHER

Principal Investigators

  • Bin Cao · China-Japan Friendship Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-10
Primary Completion
2025-07-10
Completion
2026-12-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06756191 on ClinicalTrials.gov